Search results for " dosing"
showing 3 items of 13 documents
Risks Associated with the Use of Garcinia as a Nutritional Complement to Lose Weight
2021
Nowadays, obesity is one of the great nutritional problems facing public health. The prevalence of this pathology has increased in a worrying way over recent years, currently reaching epidemic proportions. In this context, nutritional supplements are presented as a therapeutic alternative to which more and more people are turning to. Nutritional supplements to lose weight based on the Garcinia plant, specifically on Garcinia cambogia, are commonly used. The active principle of this plant to which these properties have been attributed, is hydroxycitric acid (HCA). The aim of the present review is to gather reported data concerning the effectiveness of nutritional supplements based on Garcini…
Takrolimus w długoterminowym leczeniu immunosupresyjnym biorców przeszczepu nerki — praktyczne wskazówki
2020
Tacrolimus got the position crucial immunosuppressive drug in a solid organ transplantation. For obtaining the best long-term results it is essential an avoidance of excessive dose lowering and maintenance stable drug concentration. The intrapatient tacrolimus concentration variability, which exerts negative impact on the graft survival, should be differentiated from fluctuation, describing distinct pharmacokinetic event, without proven clinical significance. Furthermore, real tacrolimus concentration variability should be separated from variability caused by recipient instability. Among causes of tacrolimus intrapatient variability on the first places are: insufficient adherence to treatme…
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…
2021
Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weight or body surface area (BSA)-based approaches may fail to fully reflect the complexity of the anthropometric features besides obesity in cancer patients suffering from sarcopenia. Likewise, there is a lack of pharmacokinetic data on obese patients for the majority of chemotherapeutic agents as well as for new target drugs and immunotherapy. Therefore, although the available findings point to the …